Immuno-Biological Laboratories Co., Ltd. (4570.T)
JPY 458.0
(-2.35%)
JPY 458.0
(-2.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 353.27 Million JPY | -0.69% |
| 2022 | 355.72 Million JPY | 5.56% |
| 2021 | 336.99 Million JPY | 61.43% |
| 2020 | 208.75 Million JPY | 10437750.0% |
| 2019 | 2000.00 JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 370 Million JPY | 4.74% |
| 2023 Q2 | 328.91 Million JPY | -2.5% |
| 2023 Q1 | 337.34 Million JPY | -5.17% |
| 2023 Q3 | 335.03 Million JPY | 1.86% |
| 2023 Q4 | 353.27 Million JPY | 5.44% |
| 2023 FY | 353.27 Million JPY | -0.69% |
| 2022 Q3 | 1000.00 JPY | -100.0% |
| 2022 FY | 355.72 Million JPY | 5.56% |
| 2022 Q4 | 355.72 Million JPY | 35572000.0% |
| 2022 Q2 | 329.43 Million JPY | 0.0% |
| 2021 FY | 336.99 Million JPY | 61.43% |
| 2020 FY | 208.75 Million JPY | 10437750.0% |
| 2019 FY | 2000.00 JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 89.12% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -457.113% |
| GNI Group Ltd. | 26.34 Billion JPY | 98.659% |
| Linical Co., Ltd. | 10.3 Billion JPY | 96.572% |
| Trans Genic Inc. | 3.81 Billion JPY | 90.734% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 40.144% |
| Soiken Holdings Inc. | 697.02 Million JPY | 49.317% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 88.305% |
| AnGes, Inc. | 2.78 Billion JPY | 87.335% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 31.218% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.609% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 78.588% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 25.211% |
| CanBas Co., Ltd. | 91.98 Million JPY | -284.04% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 67.697% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 56.377% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 40.5% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 91.696% |
| PeptiDream Inc. | 29.11 Billion JPY | 98.787% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 37.64% |
| Ribomic Inc. | 155.8 Million JPY | -126.733% |
| SanBio Company Limited | 2.25 Billion JPY | 84.333% |
| Healios K.K. | 11.28 Billion JPY | 96.87% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -40.595% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 4.263% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -46.284% |
| StemRIM | 187 Million JPY | -88.915% |
| CellSource Co., Ltd. | 677.73 Million JPY | 47.875% |
| FunPep Company Limited | 189.32 Million JPY | -86.596% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 40.821% |
| Stella Pharma Corporation | 1.44 Billion JPY | 75.529% |
| TMS Co., Ltd. | 97.68 Million JPY | -261.628% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -286.114% |
| Cuorips Inc. | 200.96 Million JPY | -75.791% |
| K Pharma,Inc. | 209.13 Million JPY | -68.921% |
| Takara Bio Inc. | 11.42 Billion JPY | 96.907% |
| ReproCELL Incorporated | 741.03 Million JPY | 52.327% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 61.505% |
| StemCell Institute Inc. | 3.85 Billion JPY | 90.825% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 61.112% |
| CellSeed Inc. | 301.04 Million JPY | -17.347% |